HOME >> MEDICINE >> NEWS
One dose of 'designer' gene therapy may target specific body area

DALLAS, Jan. 20 Doctors may soon be able to inject gene therapy intravenously that travels to a specific part of the body, according to a study published in today's rapid access issue of Circulation: Journal of the American Heart Association.

"It may be possible to design and construct genetically engineered 'designer' gene therapy for selectively delivering genes to any part of the body," said Andrew H. Baker, Ph.D., lead investigator of the study and a reader in molecular medicine at the University of Glasgow in Scotland. "We can't do that now because much of what's injected would be sequestered by the liver." The liver cleanses the blood of foreign material, among other functions.

Gene therapy involves inserting the treatment genes into a virus that is either harmless to humans or has had its disease-causing component removed. The virus is then injected or inserted into the body where it "infects" an area with gene therapy.

Baker's team redesigned a virus called adeno-associated virus (AAV) so that it is not quarantined by the liver, but rather remained in the bloodstream long enough to "infect" specific cells in the body -- in this case, the vascular endothelial cells (ECs). The new therapy targets vascular endothelial cells, which line the inside of blood vessels.

"Vascular endothelial cells, which are in continuous contact with the bloodstream and integrally involved in cardiovascular abnormalities, are appropriate targets for gene therapy," Baker said.

Baker said that AAV is important because it has the potential for long-term gene expression from a single dose. This is based on results from hemophilia studies from other laboratories in which the virus was used to deliver gene therapy. In these studies, Baker said that a single dose could last up to five years, possibly longer as the studies are ongoing. AAV is also a good choice because it does not cause disease in humans.

"The concept of developing systematica
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
19-Jan-2004


Page: 1 2

Related medicine news :

1. Study shows patch therapy may be as effective as oral medications
2. Novel therapy tested in mice could chase away cat allergies
3. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack
4. Risk of cardiac death after radiotherapy for breast cancer has declined, study finds
5. Antiretroviral therapy may prevent excess risk of some cancers in people with HIV
6. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
7. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
8. Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit
9. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
10. Cognitive behavioral therapy and medication is effective in the treatment of panic disorder
11. Study finds drug eluting stents as effective as vascular brachytherapy in preventing restenosis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a ... Mahon was named a 2017 Top Patient Rated Henderson Dentist by Find ... that recognizes local physicians and dentists who have earned high ratings and superior patient ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Phoenix, announced today that it will soon begin franchising throughout the U.S. starting ... mission to help bring the practice of meditation mainstream. Current Meditation will be ...
(Date:2/23/2017)... , ... ... the perfect opportunity for the nation to come together to ... basketball bracket – with its favorite fruit – apples! To ... apple lovers to join the “Apple Madness” bracket tournament – ...
(Date:2/23/2017)... ... ... Curemark, LLC announced today that the Blüm Study, a Phase 3 clinical ... Autism, is now enrolling at three new sites. These new sites are in addition ... “There are currently no approved drugs that address the core symptoms of autism,” said ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Limited, ( ASX: ITD ), an innovative diversified healthcare company, is ... December 2016 compared with the previous corresponding period. A full "Results ... . Highlights Profit after ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up ... 11%) Profit before tax of $2.12m (Dec 2015: ...
(Date:2/23/2017)... Feb. 23, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Fibromyalgia Drugs ... benchmarks in the global Fibromyalgia market. The research answers ... drugs marketed for Fibromyalgia and their clinical attributes? How are they ...
(Date:2/23/2017)... Research and Markets has announced the addition ... Forecast to 2025" report to their offering. ... The Global Endoscopy Market is ... next decade to reach approximately $47.6 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Medicine Technology:
Cached News: